$STVN

Stocchi Mauro sold $293K of STVN

Stocchi Mauro (See Remarks) sold 13,649 shares of Stevanato Group S.p.A. (STVN) at $21.50 ($0.29M total) on 2026-09-28.

Original reporting
SEC EDGAR · Stocchi Mauro
Published Sep 30, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 9:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STVN
Bearish
medium confidence
Mentioned
$STVN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STVNBearishLow
01

Why it matters

The disclosed sale is modest in size and may not materially affect the stock price, but it provides a data point for monitoring insider activity.

02

Market read

A routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 4/10Novelty 4/10Timing: after-hours filing on 2026-09-30

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$STVNBearishMedium confidence
Context

Officer Mauro Stocchi sold 13,649 shares of Stevanato Group at $21.50 each, total $293,453.50, reducing his holdings to 400,000 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

The transaction size is relatively small for a mid‑cap issuer and represents a reduction in insider ownership, which can be interpreted as a weak signal.

Market effects

Minimal impact on the medical device sector.

Limited to investors tracking Stevanato Group.

None

Counterpoint

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Stevanato Group S.p.A.

    Italian medical device manufacturer listed on NYSE under STVN.

  • Mauro Stocchi

    Officer of Stevanato Group who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STVNMedAI 8/10

Stevanato Group S.p.A. Q2 2026 Earnings Call Summary

Stevanato Group reported Q2 2026 revenue up 8%, with Biopharmaceutical and Diagnostic Solutions rising 9% and Engineering slightly down. High-value solutions grew 16% to 45% of revenue. Full-year 2026 guidance was raised to EUR 1.260-1.280 billion, citing a EUR 15 million Balda divestiture headwind. Alina variable dose pen received European regulatory approvals for liraglutide therapies.

$STVNMed

Stevanato (STVN) Q2 2026 Earnings Call Transcript

Stevanato Group (STVN) reported Q2 2026 revenue of EUR 302 million, up 8% year over year. High-value solutions rose 16% to EUR 135.9 million and were 45% of revenue. Gross margin increased 60 bps to 28.7%. Stevanato completed the sale of its California subsidiary Balda C. Brewer, recording EUR 12.2 million one-time expenses.

$STVNMed

Stevanato Group S.p.A. (STVN): Financial results for Q2 2026

Stevanato Group S.p.A. (STVN) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026 - The Company Divests its California-Based Subsidiary, Balda C. Brewer, Inc - (PIOMBINO DESE, Italy) – August 4, 2026 – Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of

$STVNMedAI 8/10

Stevanato Group S.p.A.: Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Stevanato Group (NYSE: STVN) reported Q2 fiscal 2026 revenue up 8% to €302.0m, with high-value solutions up 16% to €135.9m (45% of sales). Adjusted EBITDA margin rose to 26.0%. The company completed the sale of its California subsidiary Balda C. Brewer, incurring €12.2m expenses, and updated FY2026 guidance to revenue €1.260-€1.280b and adjusted EBITDA €335.0-€345.2m.